Novavax Earnings
NASDAQ: NVAXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Next earnings date
Thu, Nov 5, 2026
Fiscal period
Sep/2026
EPS estimate
$-0.38
Novavax earnings summary
Novavax is scheduled to report Sep/2026 earnings on Nov 5, 2026, with analysts expecting EPS of $-0.38. In its most recent report on Aug 6, 2026 (Q2 2026), NVAX posted EPS of $-0.32. Revenue for the quarter was $56.7 million.
Quarterly EPS is down 151.6% from the same quarter a year earlier. Across the last 16 reports, NVAX shares moved an average of 11.6% (in either direction) in the first trading session after results, rising 8 times and falling 8 times.
Summary generated from market data by MetaCap's automated system. Methodology
NVAX earnings history
| Report date | EPS est. | EPS actual | Surprise | Price reaction |
|---|---|---|---|---|
| Aug 6, 2026 | — | $-0.32 | — | +1.3% |
| May 6, 2026 | — | $-0.06 | — | -10.4% |
| Feb 26, 2026 | — | $0.28 | — | -1.6% |
| Nov 6, 2025 | — | $-1.25 | — | -6.3% |
| Aug 6, 2025 | — | $0.62 | — | +14.5% |
| May 8, 2025 | — | $2.93 | — | +12.5% |
| Feb 27, 2025 | — | $-0.41 | — | +0.1% |
| Nov 12, 2024 | — | $-0.76 | — | +15.7% |
| Aug 8, 2024 | — | $0.99 | — | +11.7% |
| May 10, 2024 | — | $-1.05 | — | +46.5% |
| Feb 28, 2024 | — | $-1.32 | — | +1.1% |
| Nov 9, 2023 | — | $-1.26 | — | -8.2% |
| Aug 8, 2023 | — | $0.58 | — | -3.0% |
| May 9, 2023 | — | $-3.41 | — | -15.4% |
| Feb 28, 2023 | — | $-2.30 | — | -15.2% |
| Nov 9, 2022 | — | $-2.15 | — | -21.5% |
Surprise compares reported EPS with the consensus estimate. Price reaction is the close-to-close move in the first session after the report. Learn about the earnings surprise.